Novartis acquired Chinook Therapeutics for up to $3.5 billion ($40.00 per share upfront plus $4.00 per share contingent value right), gaining atrasentan and zigakibart (BION-1301), two late-stage assets for IgA nephropathy (IgAN) and other kidney diseases.
Key facts
AnnouncedJun 26, 2023
ClosedAug 11, 2023
Deal value$3.5B
Deal typeAcquisition/Merger
Therapeutic areaNephrology
IndicationsIgA Nephropathy
Key assetsatrasentan, zigakibart (BION-1301)
MechanismEndothelin A receptor antagonist (ERA), Anti-APRIL monoclonal antibody